secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kronos Bio, Inc. (—)
CIK:        0001741830
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0001140361-23-044241
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kronos Bio names Sandra Gardiner interim CFO starting Sept 15, 2023
-------------------------------------------------------------------

- Appointed interim CFO, principal financial and accounting officer effective at close of business Sept 15, 2023.
- Compensation: $650 per hour paid to FLG Partners under consulting agreement; no direct employment with Kronos.
- Gardiner previously served as CFO of Pulse Biosciences (PLSE) from Nov 2019 to Dec 2022 and Cutera (CUTR) from July 2017 to Nov 2019.
- She currently serves as acting CFO of Anebulo Pharmaceuticals (ANEB) under an agreement ending Sept 28, 2023.
- Agreement with FLG is terminable by either party on 30 days' notice; includes standard indemnification provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1741830/000114036123044241/0001140361-23-044241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1741830/000114036123044241/ef20010826_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-044241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer